Home / Analysis kits / BCR-ABL1 Screening dPCR OncoKit

BCR-ABL1 Screening dPCR OncoKit

Description

Detection and quantification of BCR-ABL1 rearrangements and ABL1 messenger RNA (mRNA) transcripts from peripheral blood complementary DNA (cDNA) samples in patients diagnosed or suspected of chronic myeloid leukemia (CML) positive for t(9;22)

Format

24 rxn (dehydrated/freeze-dried)

Technology

Digital PCR (dPCR)

Reference

IMG-424

Compatible equipment

QuantStudio^TM Absolute Q Digital PCR System (ThermoFisher Scientific)

Request Kit

Characteristics
Technology
Technical specifications
Documentation

Quantitative multiplex assay: detection and quantification of BCR-ABL1 rearrangements and ABL1 mRNA transcripts from complementary DNA (cDNA) samples extracted from peripheral blood by dPCR.
BCR-ABL1 Screening dPCR OncoKit is intended for use in research and is aimed exclusively at healthcare workers and professionals working in molecular biology.

BCR-ABL1 Screening dPCR OncoKit is designed to detect and quantify BCR-ABL1 and ABL1 messenger RNA (mRNA) transcripts. The kit utilizes digital PCR (dPCR), a highly sensitive, precise, and accurate end-point PCR method that allows absolute quantification of a sample subdivided into 20,000 partitions.

The kit employs a combination of oligonucleotides and fluorescent hydrolysis probes in a multiplex assay for relative quantification of the mutated allele against the wild-type allele.

Sample type: cDNA from peripheral blood.
Positive control: Synthetic Synthetic DNA with the 3 rearrangements, M-BCR, m-BCR and µ-BCR, and a ABL1 region as the endogenous control
Limit of detection: 0,1%
Number of reactions per sample: 1
Number of targets: 3 (M-BCR, m-BCR and µ-BCR fusions and ABL1 region of endogenous)
Duration of the dPCR program: 1 h 45 min.

BCR-ABL1 Screening dPCR OncoKit: Instructions for use

BCR-ABL1 Screening dPCR OncoKit: MSDS (english)

Analysis certificate

Related kits